Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a multi-center, randomized, controlled Phase II/III clinical study. The study will assess the efficacy and safety of its programmed death-1 (PD-1) monoclonal antibody (mAb) camrelizumab in combination with Hutchmed Ltd’s (NASDAQ: HCM; HKG: 0013) multi-kinase inhibitor Sulanda (surufatinib) plus chemotherapy for first-line metastatic pancreatic cancer.
Camrelizumab, first approved in China in May 2019 for use as a third-line treatment for classic Hodgkin’s lymphoma, has chalked up nine indication approvals to date. These approvals cover a range of cancers including lung, liver, esophageal, and nasopharyngeal carcinoma, as well as lymphoma. Eight of these indications are included in the National Reimbursement Drug List (NRDL).
Hutchmed’s Sulanda, on the other hand, was approved as a treatment for advanced non-pancreatic neuroendocrine tumors (NETs) in June 2021, following its initial approval in China for advanced pancreatic neuroendocrine tumors (pNETs) in December 2020.- Flcube.com
